| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -4.8 | -7.5 |
| Net income | -4.8 | -6.4 |
| EPS (diluted, $ a share) | $-0.00 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AKTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Akari Therapeutics Plc: key numbers
- Share price
- $5.70Close, Nov 17
- Shares outstanding
- 186.09BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Akari Therapeutics Plc
All →Akari Therapeutics Financial Results
Akari Therapeutics reported third quarter 2026 financial results and highlighted the initiation of GLP toxicology studies for its lead TROP2-targeted ADC candidate, AKTX-101. The company ended the quarter with $5.7 million in cash and is progressing toward a planned Phase 1 clinical trial in mid-2027, subject to additional financing.
- Term
- Q3 2026
“We are entering an increasingly important phase in Akari’s evolution, as we translate the differentiated potential of our PH1 payload platform into a defined path toward clinical development. The initiation of GLP toxicology studies represents a critical step toward bringing AKTX-101 into the clinic.”
Abizer Gaslightwala, President and Chief Executive Officer
“The ADC landscape is rapidly evolving, and we believe the next wave of innovation will be driven not simply by new targets, but by novel payloads capable of overcoming the limitations of current treatments. That is precisely the opportunity we are pursuing with the PH1 payload.”
Abizer Gaslightwala, President and Chief Executive Officer
Akari Therapeutics Stock Plan Amendment
Akari Therapeutics held a Special General Meeting where shareholders approved an amendment to the 2023 Equity Incentive Plan. The amendment increases the number of ordinary shares available for issuance by 144 billion shares, equivalent to 1.8 million American Depositary Shares (ADSs).
Akari Therapeutics Stock Plan Amendment
Akari Therapeutics amended its agreement with CEO Abizer Gaslightwala to increase his base salary to $625,000 and his target bonus to 55%. The amendment includes a grant of 174,000 ADS options and restricted stock units, both of which are subject to shareholder approval of an amendment to the company's 2023 Equity Incentive Plan to increase the share pool.